Table 1

Patient demographics

Organ involvement
All patientsLungSkinEye
Number2071845445
Age, years, mean (SD)48 (11)48 (11)47 (9)49 (13)
Women, n (%)112 (54)98 (53)31 (57)28 (62)
Ethnicity, n (%)
 Caucasian120 (58)105 (57)17 (31)19 (42)
 Afro-Caribbean62 (30)57 (31)30 (57)20 (44)
 South Asian*21 (10)18 (10)5 (9)5 (11)
 Other4 (2)4 (2)2 (4)1 (3)
Smoking status, n (%)
 Current25 (12)24 (13)3 (6)3 (7)
 Ex56 (27)51 (28)13 (24)16 (35)
 Never126 (61)109 (59)38 (70)26 (58)
Time since diagnosis, years, mean (SD)7.7(6.6)7.5 (6.2)6.9 (4.9)6.9 (5.9)
Organs involved, n (%)
 Lungs184 (89)
 Skin54 (26)
 Eyes45 (22)
 Nervous system9 (4)
 Ear, nose and throat7 (3)
 Liver8 (4)
 Lymph nodes6 (3)
 Bone and joints17 (8)
 Other14 (7)
Number of organs involved1.8 (0.9)1.8 (0.9)2.6 (0.9)2.7 (0.8)
Physician Global Assessment (Skin)1.4 (0.93)
Visual acuity (best eye), n (%)
 Normal25 (56)
 Moderate impairment14 (31)
 Severe impairment6 (13)
FEV1% predicted, mean (SD)76 (24)
FVC% predicted, mean (SD)93 (18)
TLCO% predicted, mean (SD)63 (16)
Immunosuppressant, n (%)
 None60 (29)
 Prednisolone139 (67)
 Methotrexate29 (14)
 Azathioprine29 (14)
 Hydroxychloroquine27 (13)
 Other immunosuppression2 (1)
  • *South Asian patients originating from India, Pakistan or Bangladesh.

  • Visual acuity: normal: <20/30; moderate impairment: >20/30 but <20/63; severe impairment: >20/63.

  • Immunosuppressant medications were those prescribed at the time of the study.

  • FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLCO, diffusing capacity of the lung for carbon monoxide as % predicted.